GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care ConferenceBusiness Wire • 03/01/23
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring CommitteeBusiness Wire • 02/15/23
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual MeetingBusiness Wire • 12/12/22
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 12/02/22
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is BrightZacks Investment Research • 11/23/22
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022Business Wire • 11/09/22
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual MeetingBusiness Wire • 11/03/22
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/07/22
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022Business Wire • 08/03/22
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare ConferenceBusiness Wire • 06/02/22
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/30/22